Alimera Sciences

ALIM · NASDAQ

Price unavailable right now.

No price history for this range.

ALIM analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Sep 14, 2024

Bull case

Alimera Sciences Inc. has demonstrated impressive financial growth, with topline revenue increasing by 49% in 2023 and a noteworthy 70% growth in the first quarter of 2024, supported by an anticipated revenue of over $105 million for the full year. The company reported net revenue of $14.6 million, reflecting a 92% year-over-year increase, while international operations also saw strong performance with a 42% increase in net revenue. With a projected adjusted EBITDA margin exceeding 20% and ongoing demand for its key products, ILUVIEN and YUTIQ, Alimera Sciences appears well-positioned for sustainable growth moving forward.

Bear case

Alimera Sciences reported a significant net loss of $3.8 million in the latest quarter, which was unexpectedly lower than an anticipated income of $0.9 million, further indicating ongoing financial challenges for the company. Additionally, the company has consistently incurred substantial net losses across reporting periods, with a total of $21.9 million, or ($0.79) per share, emphasizing the financial instability that raises concerns about its future profitability. The firm faces multiple risks, including the potential failure to secure additional regulatory approvals for ILUVIEN, the uncertain commercial success of its products due to market dynamics and competition, and potential dilution risks, which collectively contribute to a negative outlook on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.